Regeneron and Bayer's DME drug shows promise in phase III trials
- Regeneron and Bayer have released results from a phase III VIVID-DME trial of Eylea (aflibercept).
- The trial Eylea injection therapy as compared with photocoagulation to determine responses in patients with diabetic macular edema (DME).
- Patients who received Eylea injections every two months had greater improvements in their eyesight -- as measured by best corrected visual acuity (BCVA) -- compared with photocoagulation-treated patients.
Eylea's VIVID-DME phase III trials are now complete after two years of study. At week 100, Eylea-treated patients who received monthly injections had an average BCVA gain of 11.4 letters -- the equivalent of being able to read more than two extra lines on a standard eye exam chart.
Patients who received bi-monthly injections had a mean gain of 9.4 letters, while photocoagulation-treated patients had an average gain of just 0.7 letters during the same time period. Full data from the clinical trial will be presented in coming months at various medical conferences.
- Pharmaceutical Business Review Regeneron, Bayer release positive Phase III trial results of EYLEA to treat DME